Company intelligence / Profile preview

Pardes Biosciences

Carlsbad, California, United Statesforesitecapital.com ↗

Ownership: Private
Development stage: Phase 1

Overview

PBI‑0451 advanced to Phase I trials as an oral antiviral targeting the coronavirus main protease. The company’s approach aimed to offer a direct‑acting therapy for COVID‑19 without the need for boosting agents. Clinical development has since been suspended and the company sought strategic alternatives. No late-stage or commercial results reported.

Therapeutic areas: Infectious Diseases
Modalities: Small moleculeProtease inhibitor
Industry: Biotech

Drug pipeline

1 asset

PBI-0451

Phase 1

Indications: COVID-19

Partnerships

Foresite CapitalMediPacific, Inc.

Beyond the preview

Go deeper on Pardes Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pardes Biosciences.

Explore the full profile